Design and Synthesis of a Novel PLK1 Inhibitor Scaffold Using a Hybridized 3D-QSAR Model

Polo-like kinase 1 (PLK1) plays an important role in cell cycle progression and proliferation in cancer cells. PLK1 also contributes to anticancer drug resistance and is a valuable target in anticancer therapeutics. To identify additional effective PLK1 inhibitors, we performed QSAR studies of two series of known PLK1 inhibitors and proposed a new structure based on a hybridized 3D-QSAR model. Given the hybridized 3D-QSAR models, we designed and synthesized 4-benzyloxy-1-(2-arylaminopyridin-4-yl)-1H-pyrazole-3-carboxamides, and we inspected its inhibitory activities to identify novel PLK1 inhibitors with decent potency and selectivity.     

5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑的合成方法概述及研究

以2,6-二氯-4-三氟甲基苯胺为原料,经重氮化和环化反应得到5-氨基-3-氰基-1-(2,6-二氯-4-三氟甲基苯基)吡唑,本方法工艺操作简单,易于工业化生产。收率85%,纯度为95%。     

吡唑及其衍生物合成研究进展

综述了吡唑衍生物合成的研究进展。吡唑衍生物的合成方法有:(1)肼与1,3-二羰基酮发生反应;(2)重氮烷烃与烯炔化合物反应;(3)肼与乙酸乙酰乙酯反应;(4)肼与丙烯腈、丙二腈衍生物反应;(5)肼与烯酮反应;(6)在合成技术上还有固相合成和微波辅助合成等。     

Synthesis and Anti-Cancer Activity of New Pyrazolinyl-Indole Derivatives: Pharmacophoric Interactions and Docking Studies for Identifying New EGFR Inhibitors

Newly designed series of indole-containing pyrazole analogs, pyrazolinylindoles, were synthesized, and their structures were confirmed based on the spectral data of the ¹H NMR, ¹³C NMR, and HR-MS analyses. Preliminary anti-cancer activity testings were carried out by the National Cancer Institute, United States of America (NCI, USA). Compounds HD02, HD05, and HD12 demonstrated remarkable cytotoxic activities against nine categories of cancer types based cell line panels which included leukemia, colon, breast, melanoma, lungs, renal, prostate, CNS, and ovarian cancer cell lines. The highest cytotoxic effects were exhibited by the compounds HD02 [1-(5-(1-H-indol-3-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-phenylethanone], HD05 [1-(3-(4-chlorophenyl)-5-(1H-indol-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)-2-phenoxyethanone], and HD12 [(3-(4-chlorophenyl)-5-(1H-indol-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)(pyridin-4-yl)methanone] against some of the 56 types of NCI-based cell lines in different panels. Compound HD05 showed the maximum range of cancer cell growth inhibitions against all categories of the cell lines in all nine panels. On average, in comparison to the referral standard, imatinib, at a dose level of 10 µM, the HD05 showed significant activity against leukemia in the range of 78.76%, as compared to the imatinib at 9% of cancer cells’ growth inhibitions. Molecular docking simulation studies were performed in silico on the epidermal growth factor receptor (EGFR) tyrosine kinase, in order to validate the activity.     

3（5）-取代-1H-吡唑甲酸及其铜配合物合成与表征

以四种不同的酮类化合物及草酸二乙酯为原料,设计合成了四种3（5）-取代-1H-吡唑甲酸化合物,通过IR及^1H NMR对所合成的化合物结构进行了表征．化合物3a与金属铜离子配位,得到一个双核铜配合物晶体,该晶体属三斜晶系,空间群为P-1,晶胞参数为a=7．082（8）A,b=9．156（10）A,c=25．86（3）A,a=97．088（19）°,β=92．024（18）°,γ=112．649（13）°,V=1529（3）A3,Z=4,Dc=1．597g/cm^3,配合物的晶体结构进一步确证了所合成化合物结构的准确性．     

N-吡唑酰基苯并咪唑衍生物的合成研究

设计合成了5个未见文献报道的N-吡唑酰基苯并咪唑类化合物,其结构经元素分析、1HNMR、IR确证.     

二硝基吡唑并吡唑（DNPP）合成工艺研究

以乙酰丙酮与水合肼为原料,经脱水缩合、一次硝化、还原、重氮化、环化、二次硝化、氧化、脱羧硝化等反应合成了DNPP,收率9.3%,并采用元素分析、红外光谱、核磁共振进行了表征;初步探讨了合成条件及环化反应历程。     

含二氟溴甲基取代的新型吡唑类化合物的合成

以二氟溴乙酸乙酯、水合肼、甲基酮、NCS、NBS等为原料,通过Claisen缩合、关环、卤代等反应合成了12个未见合成文献报道的含二氟溴甲基取代的吡唑类化合物,其结构均通过1HNMR、13CNMR和HRMS表征。合成中对关环条件进行了优化,合成3-二氟溴甲基-5-烷基-1H-吡唑的反应收率均达90%以上。     

微波辐射合成1,3-二苯基-4-甲酰基吡唑

在微波辐射下,以苯肼和苯乙酮为原料,经脱水和Vislmeier环合反应,简便、高效地合成1,3-二苯基-4-甲酰基吡唑,并对微波辐射下的原料配比、反应温度和辐射时间等反应条件进行优化。     

1-甲基-3-正丙基-5-吡唑羧酸的合成研究

以草酸二乙酯和2 戊酮为原料,经claiseen酯缩合、环化、水解三步反应合成出1 甲基 3 正丙基 5 吡唑羧酸,总收率73.26%,化合物用红外、核磁、元素分析等手段进行了结构表征。